PT Astellas Pharma Indonesia was established in the year 2000 as P.T. Yamanouchi Indonesia, a subsidiary of Yamanouchi Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan On April 1st, 2005, Astellas Pharma Inc. was established through a merger of Yamanouchi Pharmaceutical Company Limited and Fujisawa Pharmaceutical Company Limited. Following this merger, PT Yamanouchi Indonesia changed its name to PT Astellas Pharma Indonesia. Being a member of the International Pharmaceutical Manufacturers Group (IPMG) in Indonesia, PT Astellas Pharma Indonesia is committed to delivering pharmaceutical products that are safe, innovative and reliable. Our products in Indonesia consisted of antifungal (Mycamine), antiplatelet (Dorner), immunosuppresant (Prograf, Prograf XL), oncology (Eligard, Xtandi), and urology (Harnal D, Harnal OCAS, Vesicare, Betmiga). Astellas is committed to providing a brighter future for our stakeholders, including patients and their families, healthcare personnel, shareholders, employees and the global community. Our communication slogan, "Changing tomorrow," express our pledge to develop new medicines that are vital to patients worldwide. At the same time, this means that Astellas hopes to share in the bravery, hope, and desires of patients.

As a research and development-oriented global pharmaceutical company, we are always working to develop innovative new drugs, especially in areas where there is a high degree of unmet medical need. Astellas' raison d'être is to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The Astellas value chain continues to grow as we expand our worldwide operations. Consequently, we need to reinforce governance on a global level, taking into account its relationships with our stakeholders throughout the value chain. Acting in accordance with "high ethical standards" is the core of our values here at Astellas. We will continue contributing to the world's sustainable development while communicating closely with all of our stakeholders. Our aim is to ensure we are a company that answers the needs of a truly global society. We are committed to transforming progress in science and technology into value for our patients.